Pfizer Halts Phase III Study Of Sutent In Advanced Breast Cancer
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Pfizer's efforts to gain a monotherapy indication for its oncologic Sutent in advanced breast cancer may have been derailed by a failed single-agent trial, but the company still has several Phase III studies of Sutent in combination with various chemotherapies that could give it an entry into the breast cancer market